Skip to main content
. 2025 Dec 8;18:7381–7393. doi: 10.2147/IJGM.S549714

Table 1.

The Clinicopathological Features of Patients with Endometrial Cancer

Clinicopathological Features Total (n = 563)
Age (years)
 <55, n (%) 223(39.6%)
 ≥55, n (%) 340(60.4%)
Reproductive history
 No, n (%) 16(2.8%)
 Yes, n (%) 547(97.2%)
Menopause
 No, n (%) 174(30.9%)
 Yes, n (%) 385(68.4%)
 Unknown, n (%) 4(0.7%)
Histological type
 Endometrioid carcinoma, n (%) 483(85.8%)
 Serous carcinoma, n (%) 33(5.9%)
 Clear cell carcinoma, n (%) 11(2.0%)
 Squamous cell carcinoma, n (%) 2(0.4%)
 Mixed carcinoma, n (%) 12(2.1%)
 Others, n (%) 7(1.2%)
 Unknown, n (%) 15(2.7%)
Tumor differentiation
 Well, n (%) 118(21.0%)
 Moderate, n (%) 313(55.6%)
 Poor, n (%) 79(14.0%)
 Unknown, n (%) 53(9.4%)
Muscular infiltration
 Endometrium, n (%) 84(14.9%)
 <1/2 muscular layer, n (%) 312(55.4%)
 ≥1/2 muscular layer, n (%) 92(16.3%)
 Unknown, n (%) 75(13.3%)
Lymphovascular invasion
 Absent, n (%) 405(71.9%)
 Present, n (%) 74(13.1%)
 Unknown, n (%) 84(14.9%)
Perineural invasion
 Absent, n (%) 469(83.3%)
 Present, n (%) 3(0.5%)
 Unknown, n (%) 91(16.2%)
Disease stage
 I, n (%) 417(74.1%)
 II, n (%) 27(4.8%)
 III, n (%) 69(12.3%)
 IV, n (%) 20(3.6%)
 Unknown, n (%) 30(5.3%)
Molecular subtypes
 dMMR 197(35.0%)
 p53 abnormal 155(27.5%)
 POLE mutant 52(9.2%)
 NSMP 159(28.2%)